Genetic analyses identify more mutations and help plan treatment for breast cancer
Three studies presented at the 2014 San Antonio Breast Cancer Symposium (SABCS): Cancer risk test detected 105% more mutations in cancer-causing genes than conventional BRCA testing alone; researchers at leading cancer research institutions validate use of companion diagnostic test to detect a DNA scar in tumor that is indicative of a dysfunctional DNA repair pathway; UK researchers evaluated the use of companion diagnostic assays to identify which patients would respond to carboplatin or docetaxel.
